A medical-record study found more weight loss after bariatric surgery than after starting GLP-1 drugs [1]. A separate comparison of cardiovascular outcomes after surgery and semaglutide focused on heart and vascular events. The studies tracked different outcomes.
What the surgery comparison found
The study included 44,025 patients. At two years, estimated weight loss was 22.4% after sleeve gastrectomy and 28.1% after gastric bypass. Estimates were 6.5% with semaglutide and 10.8% with tirzepatide [1].
Treatment was not randomly assigned. Differences in why people chose each treatment may affect the results. Medication doses, treatment duration and follow-up also varied.
Why results vary outside trials
A review of routine care found that tolerability and access can affect how long patients stay on treatment [2]. Studies of GLP-1 treatment persistence help explain why a trial and a health record cohort can produce different weight estimates.
The review also considered structured lifestyle programs, endoscopic procedures and other medicines. Those data come from studies with different patients and follow-up periods. A comparison of averages cannot identify the best treatment for every patient.